Pharmaceutical companies have never lacked data. What they have lacked is speed. It is this inefficiency that has driven investor interest in BranchLab, a US-based health technology startup aiming to modernise how pharmaceutical companies turn data into action.

The company has secured $26 million in a Series A funding round led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The raise brings BranchLab’s total funding to $35 million.

In a statement shared on LinkedIn, the company described the milestone as a step towards “a fundamental shift in healthcare commercialisation”.

“Pharma has long had access to rich data, but using it quickly—and responsibly—has been the challenge,” said Josh Walsh, CEO of BranchLab. “BranchLab solves this by turning privacy-safe, aggregated data into real-time insights that connect directly to activation.”

A Persistent Bottleneck in Pharma

Despite years of investment in analytics and digital tools, pharmaceutical marketing remains constrained by legacy workflows.

Audience targeting, patient outreach, and campaign measurement are often handled through disconnected vendors and siloed platforms. Data must pass through multiple compliance layers before it can be used, creating delays that undermine responsiveness.

This structural lag has real consequences. It raises customer acquisition costs, weakens campaign performance, and limits the ability of companies to connect patients with appropriate therapies at the right time.

BranchLab’s proposition is simple: compress these timelines from months into minutes.

Turning Data into Action Without Breaking Privacy Rules

At the centre of BranchLab’s platform is an artificial intelligence system designed to operate within regulated healthcare environments.

Rather than relying on individual-level health records, the platform uses aggregated, non-sensitive data combined with media and demographic signals. Its transformer-based architecture allows models to run inside customer-controlled systems, reducing the risk of data exposure.

According to Josh Walsh, the goal is to bridge a long-standing gap in the industry.

“Teams can move faster, reach the right audiences more effectively, and drive better outcomes without relying on sensitive or individual-level information,” said Walsh.

The company claims its platform has delivered an average increase of nearly 70 per cent in marketing effectiveness across multiple therapeutic areas, although these figures have not been independently verified.

Investor Bet on Compliance-Safe AI

The funding round reflects a broader shift in how investors view artificial intelligence in healthcare.

Rather than backing generic AI tools, venture capital is increasingly flowing into companies that can navigate the regulatory complexity of sectors such as pharmaceuticals, insurance, and clinical care.

For investors, the appeal lies in infrastructure. Systems that can operate within compliance frameworks and integrate directly into enterprise environments are seen as more defensible and scalable.

The pharmaceutical industry’s data problem is not just about volume. It is about fragmentation.

Large drugmakers have spent years building data lakes, analytics platforms, and customer relationship systems. Yet much of this infrastructure remains disconnected from execution.

The Compliance Challenge

Any attempt to modernise healthcare marketing must confront one central issue: patient privacy.

Strict regulations governing the use of health data have slowed the adoption of AI across the pharmaceutical sector. Companies must balance innovation with compliance, often erring on the side of caution.

BranchLab’s decision to avoid individual-level data is therefore strategic. By focusing on aggregated insights, the company aims to reduce regulatory friction while still delivering actionable intelligence.

BranchLab’s platform attempts to close that gap by embedding intelligence directly into campaign workflows. This allows teams to identify audiences, activate campaigns, and optimise performance in near real time.

Implications for Global and African Markets

While BranchLab is currently focused on developed healthcare markets, the implications of its model extend globally.

In regions such as Africa, where pharmaceutical access remains uneven and marketing infrastructure is less mature, real-time, data-driven systems could offer a different kind of leapfrog opportunity.

Healthcare providers and drugmakers across the continent face similar challenges: fragmented data systems, limited patient visibility, and high distribution costs. AI platforms that operate without sensitive personal data could prove particularly relevant in environments with evolving regulatory frameworks.

For multinational pharmaceutical companies operating in Africa, tools that improve targeting and reduce waste in marketing spend could also support more efficient therapy distribution.

BranchLab plans to use the new funding to expand enterprise deployments, deepen integrations across healthcare and media systems, and continue developing its platform.

The company is positioning itself not just as a marketing tool, but as a foundational layer for pharmaceutical commercial operations.

Talking Points

It is notable that BranchLab is tackling a long-standing inefficiency in the pharmaceutical industry, where access to data has never been the problem, but the ability to act on it quickly has remained a persistent challenge.

By focusing on speed and execution, the company is addressing a critical gap in healthcare commercialisation, where delayed insights often translate into missed opportunities for both businesses and patients.

At Techparley, we see how BranchLab’s privacy-first approach stands out, particularly in an industry where compliance concerns have slowed the adoption of AI despite its clear potential.

The decision to rely on aggregated, non-sensitive data rather than individual patient records positions the platform as both practical and scalable within highly regulated environments.

The promise of compressing workflows from months into minutes signals a significant shift, especially for pharmaceutical companies seeking to reduce customer acquisition costs and improve therapy adoption rates.

As BranchLab expands, partnerships with major healthcare players and deeper integration into enterprise ecosystems could determine how quickly it scales and how deeply it embeds itself within industry workflows.

——————-

Bookmark Techparley.com for the most insightful technology news from the African continent.

Follow us on Twitter @Techparleynews, on Facebook at Techparley Africa, on LinkedIn at Techparley Africa, or on Instagram at Techparleynews.